Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.

BMC Cancer · 2021 · PMC8527794 · PMID 34670506

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

A borderline significant distinction was observed in the median OS between the two cohorts (17.7 months [95% CI, 15.2–18.3] in the PLH-treated cohort vs. 12.6 months [95% CI, 11.1–13.7] in the PL-treated cohort), as shown in Fig. 2 .

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.